Join to View Full Profile
Elm and Carlton StBuffalo, NY 14263
Dr. Davila is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Marco Davila, MD, is an oncology specialist based in Buffalo, NY, with a subspecialty in hematologic oncology. He earned his medical degree from Duke University School of Medicine and completed his fellowship in hematology and medical oncology at Memorial Sloan Kettering Cancer Center. Dr. Davila holds the positions of Senior Member and Vice Chair for Cellular Immunotherapies at Roswell Park Cancer Institute. His expertise includes immunotherapy, hematologic oncology, and CAR-T cell therapy. He has contributed to numerous published research studies and clinical trials, and has been recognized with several honors and awards, including the Young Physician-Scientist Award from the ASCI Council.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2006 - 2010
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2004 - 2006
Duke University School of MedicineClass of 2004
Texas Christian UniversityBS, Biology/Chemistry, Summa Cum Laude, 1991 - 1995
Certifications & Licensure
FL State Medical License 2015 - 2027
NY State Medical License 2006 - 2027
TN State Medical License 2013 - 2015
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Young Physician-Scientist Award ASCI Council, 2014
- Amos Medical Faculty Development Program Scholar American Society of Hematology, 2012
- TRiO Achiever Award Texas Christian University, 2011
Clinical Trials
- Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 Start of enrollment: 2010 Jan 05
- CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML Start of enrollment: 2021 Jan 14
Publications & Presentations
PubMed
- Synthetic lethality of MCL-1 inhibition and CAR-T therapy in aggressive B-cell lymphoma.Jing Gao, Xiaohong Zhao, Qing Yin, Allen Hu, Kevin Qiu
Leukemia. 2026-02-12 - 1 citationsIL-36γ armored CAR T cells reprogram neutrophils to induce endogenous antitumor immunity.Yihan Zuo, David J Vohwinkel, Bowen Dong, James R McDowell, Brandon V Guzman
Cancer Cell. 2026-02-09 - Endogenous CD28 drives the persistent activity of CAR T cells in myeloma and lymphoma models.Mackenzie M Lieberman, Jason H Tong, Nkechi U Odukwe, Colin A Chavel, Gina G Bishara
Blood Cancer Discovery. 2026-02-02
Journal Articles
- CARs move to the Fast LaneDavila ML and Papetrou E, Molecular Therapy, 1/1/2014
- Chimeric Antigen Receptors for the Adoptive T Cell Therapy Of Hematologic MalignanciesDavila, ML, Bouhassira DC, Park JH, Curran KJ, Smith EL, Pegram HJ, and Brentjens R., International Journal of Hematology, 1/1/2014
- Chimeric Antigen Receptor Therapy for Chronic Lymphocytic Leukemia: What are the Challenges?Davila ML, Brentjens R, Hematol Oncol Clin North Am, 1/1/2013
Abstracts/Posters
- Human CD83 Targeted Chimeric Antigen Receptor T Cell for the Prevention of Graft Versus Host Disease and Treatment of Myeloid LeukemiaMarco L. Davila, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- The Lymphoma Tumor Microenvironment Influences Toxicity after CD19 CAR T Cell TherapyMarco L. Davila, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Mutation of the CD28 Co-Stimulatory Domain Confers Enhanced CAR T Cell FunctionMarco L. Davila, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- Prediction of CAR T-Related Toxicities in R/R DLBCL Patients Treated with Axicabtagene Ciloleucel Using Point of Care Cytokine Measurements2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-Based CAR-T Therapy, Cyad-01, in Acute Myeloid Leukemia2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Aged CAR T Cells Exhibit Enhanced Cytotoxicity and Effector Function but Shorter Persistence and Less Memory-like Phenotypes2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Roswell Park Experts Share Latest Hematology Research at 67th ASH Annual MeetingNovember 6th, 2025- Research Leaders Across New York State Form Empire State Cellular Therapy ConsortiumJuly 10th, 2025
- ASCO 2025 Highlights: Menin Inhibitor for Acute Myeloid Leukemia; Organ Transplant and Checkpoint InhibitorsMay 23rd, 2025
Grant Support
- Targeting CD83 to reduce leukemia relapse and GVHD after allogeneichematopoietic cell transplantationROSWELL PARK CANCER INSTITUTE CORP2023–2028
- The Adoptive Transfer Of Gene-Modified T Cells As A Cell Therapy For LymphomaNational Cancer Institute2010–2011
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
